Abstract

Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate

Author(s): Reed-Kane Dana, Kirshbaum Karen

Issue: May/Jun 2006 - Hormone Replacement Therapy

Page(s): 165-171

Download in electronic PDF format for $75

Abstract

17a-hydroxyprogesterone caproate is a naturally occurring metabolite of progesterone that is produced in significant quantities during pregnancy. The demand for 17a hydroxyprogesterone caproate, the lack of a commercially available manufactured form approved by the US Food and Drug Administration, and publication of the results of a large trial to determine the effectiveness of the drug in the prevention of preterm delivery have spawned an increased interest in compounded formulations of the drug. The demand also has necessitated a review of the available literature and of past clinical studies, and a look at present and planned studies. Owing to the importance of this drug in pregnancy and the need for safety, accuracy in potency, and sterility in an intramuscular injection (the most common route of administration), compounding pharmacies must be in compliance with the United States Pharmacopeia Chapter <797> standards should they wish to compound this formulation.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2006 Pg. 165-171	Prevention of Preterm Delivery with Compounded 17a-Hydroxyprogesterone Caproate Author(s): Reed-Kane Dana, Kirshbaum Karen
May/Jun 2006 Pg. 172	Case Report: Hydroxyprogesterone Caproate Injection for Prevention of Preterm Labor Author(s): Fields Shannon W
Nov/Dec 2011 Pg. 446-448	A Retrospective Observational Case Series Analysis of the Usage of Hydroxyprogesterone Caproate for the Prevention of Preterm Labor in Alabama Patients Author(s): Nolan Sara M, Burgess Christopher A
Jul/Aug 2003 Pg. 299	Hydroxyprogesterone Caproate 250-mg/mL-in-Oil Injection Author(s): Allen Loyd V Jr
Jan/Feb 2012 Pg. 86-87	PostScription: Best Practice Recommendations for Compounding 17-Hydroxyprogesterone Author(s): Cabaleiro Joe
Jan/Feb 2013 Pg. 74-85 View Sample	The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Sep/Oct 2003 Pg. 330-338	A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Author(s): Gillson George R, Zava David T
Jul/Aug 2008 Pg. 295-304	Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K, Pinson Barbara, Price Carol
Jan/Feb 2004 Pg. 10-14	Women's Oral Health: Is There a Hormonal Link? Author(s): Preckshot John
Jan/Feb 2004 Pg. 16-21	Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1 Author(s): Cutter Christopher B
Mar/Apr 2018 Pg. 108-121	Personalized Medicine and Customized Drug Delivery Systems: The New Trend of Drug Delivery and Disease Management Author(s): Soni Abhishek, Gowthamarajan Kuppusamy, Radhakrishnan Arun
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Jan/Feb 2019 Pg. 62-64	Chemical Stability of Progesterone in Compounded Oral Rapid-dissolving Tablets Author(s): Sayre Casey L, Cox Christopher, Velazquez Gabriel, Le Minh Thi, Nguyen Amy Hong, Ramos Marjorie, Burrows Anna, Yellepeddi Venkata Kashyap
Nov/Dec 2022 Pg. 446-466	Compounding with Biotechnology Products, Part 2: Product-specific Considerations Author(s): Allen Loyd V Jr
Jan/Feb 2019 Pg. 14-21	The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2 Author(s): Williams LaVonn A
Mar/Apr 2004 Pg. 96-99	Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2 Author(s): Cutter Christopher B
Jul/Aug 2018 Pg. 284-287	The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 1 Author(s): Williams LaVonn
Nov/Dec 2017 Pg. 530-535	Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives Author(s): Trimble John O, Light Bob
Nov/Dec 2015 Pg. 491-500	Basics of Sterile Compounding: Sterile Product Packaging and Delivery Systems Author(s): Akers Michael J
Jan/Feb 2023 Pg. 30-37	Advanced Compounding: Compounding with Microneedle Arrays, Part 3: Microneedle Array Development in the Literature and Quality Control of Microneedle Arrays Author(s): Allen Loyd V Jr